VIRMA and intrahepatic cholangiocarcinoma: VIRMA can maintain the stability of TMED2 and PARD3B through m6A HuR mediation, activate the Akt/GSK/β- catenin and MEK/ERK/Slug signaling pathways, thereby promoting further deterioration of intrahepatic cholangiocarcinoma (ICC) (183).